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Abstract The ﬁbrinous exudate of a wound or tumor
stroma facilitates angiogenesis. We studied the involvement
of RGD-binding integrins during tube formation in human
plasma-derived ﬁbrin clots and human puriﬁed ﬁbrin
matrices. Capillary-like tube formation by human micro-
vascular endothelial cells in a 3D plasma-derived ﬁbrinous
matrix was induced by FGF-2 and TNF-a and depended
largely on cell-bound u-PA and plasmin activities. While
tube formation was minimally affected by the addition of
either the avb3-integrin inhibiting mAb LM609 or the a5-
integrin inhibiting mAb IIA1, the general RGD-antagonist
echistatin completely inhibited this process. Remarkably,
when avb3- and a5b1-integrins were inhibited simulta-
neously, tube formation was reduced by 78%. It was
accompanied by a 44% reduction of u-PA antigen accu-
mulation and 41% less production of ﬁbrin degradation
products. avb5-integrin-blocking antibodies further
enhanced the inhibition by mAb LM609 and mAb IIA1 to
94%, but had no effect by themselves. av-speciﬁc cRGD
only inhibited angiogenesis when a5b1-integrin was
simultaneously blocked. Endostatin mimicked the effect of
a5b1-integrin and inhibited tube formation only in the
presence of LM609 or cRGD (73 and 80%, respectively).
Comparable results were obtained when puriﬁed ﬁbrin
matrices were used instead of the plasma-derived ﬁbrinous
matrices.Thesedatashowthatblockingoftubeformationin
a ﬁbrinous exudate requires the simultaneous inhibition of
avb3-anda5b1-integrins.Thismaybearimpactonattempts
to inﬂuence angiogenesis in a ﬁbrinous environment.
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Introduction
Angiogenesis, the outgrowth of new microvascular struc-
tures from the preexisting vasculature, is pivotal for
embryonic development [1]. Once the organism has
become adult, angiogenesis is limited to the endometrium
and ovary. However, as part of normal or deranged tissue-
repair processes, it is induced after wounding and in a
number of diseases, such as cancer, diabetic retinopathy,
and rheumatoid arthritis [1, 2]. Repair-associated angio-
genesis is normally accompanied by ﬁbrin deposition and
accumulation of cytokine-producing leukocytes [3–6]. The
leakiness of tumor vessels and the presence of tissue factor
in the interstitial tissue favor the deposition of a ﬁbrinous
matrix as part of the tumor stroma. Such a ﬁbrinous matrix
provides excellent scaffolding for the invasion of new
vascular structures [4, 7, 8]. Thus, the temporary ﬁbrinous
scaffolding not only plays an important role in wound
closure, but also supports cell invasion and angiogenesis in
tumor stroma and in inﬂamed tissues.
The induction and activity of cell-bound proteolytic
activities and matrix-binding receptors largely regulate the
migration and invasion of endothelial cells during angio-
genesis, in addition to structural epitopes in the extracellular
or ﬁbrinous matrix itself [9]. Both the cell-bound urokinase
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(MMPs), in particular membrane-type MMPs (MT-MMPs),
play a pivotal role in migration and invasion of endothelial
cells during the formation of tubular structures in a ﬁbrin
matrix [9–14].
Besides proteolysis, the formation of new adhesion sites
between the invading cells and the matrix is required.
Among the various types of adhesion molecules, the inte-
grins particularly play an important role in tissue repair and
tumor-induced angiogenesis [15–18]. Integrins are trans-
membrane glycoproteins consisting of noncovalently
linked a- and b-subunits, which can form various hetero-
dimers [18, 19]. Presently, nine integrins have been rec-
ognized on endothelial cells [19]. The RGD-recognizing
integrins avb3-, avb5-, and a5b1 facilitate cell binding to
ﬁbrin [20] and are expressed on the endothelial cells of
newly formed vessels in a ﬁbrinous matrix of wounds
and tumors [21–23]. Quantitative alterations in avb3- and
a5b1-integrin expression in particular, modulate the
adhesive and migratory properties of endothelial cells
during angiogenesis in wound repair and tumor growth [24,
25]. This can be induced by provisional matrix molecules
in the wound clot, such as ﬁbrin, and local conditions, such
as hypoxia [26, 27]. On the basis of the inhibitory activities
of av- and avb3-integrin antagonists, such as cRGD pep-
tides and antibody LM609, on angiogenesis in several
pathological conditions in animals it was postulated that
such antagonist may be good candidates for inhibiting
tumor angiogenesis [21]. However, this concept was
challenged by the ﬁnding of Reynolds et al. [28, 29] that
mice lacking b3-integrins or both b3- and b5-integrins
support tumor angiogenesis and tumor growth. This data
indicates that the role of av-integrins in angiogenesis is
more complex than originally thought [30–32]. In addition
to avb3 inhibition, blocking of a5b1 can contribute to the
regulation of angiogenesis [23]. The a5b1-integrin and
other integrins have been shown to be targets for endo-
statin, the C-terminal fragment of collagen XVIII [33, 34]
which can strongly suppress tumor-induced angiogenesis in
animals [35–37].
The formation of capillary-like structures in a ﬁbrinous
exudate can be mimicked by human microvascular endo-
thelial cells (hMVECs) in a 3D-ﬁbrin matrix [11]. With this
model we reported previously that inhibition of avb3-
integrin activity by LM609 did not reduce the formation of
capillary-like structures by hMVECs in a ﬁbrin matrix [27].
Subsequently we observed that inhibition of RGD-binding
integrins by echistatin prevented tube formation. Because
both a5b1- and av-integrins are involved in the binding of
endothelial cells to a ﬁbrinous matrix and may inﬂuence
their activities mutually, we further evaluated how various
RGD-binding integrins cooperate in the formation of cap-
illary-like structures. This was studied both in a ﬁbrin
matrix and in 3D-matrices consisting of a plasma clot to
mimic the ﬁbrinous exudate more closely. The involvement
of RGD-binding integrins during neovascularization could
also be demonstrated by tube formation in the murine
ﬁbrinous exudate.
Materials and methods
Materials
Cell culture reagents were purchased as previously
described [38]. Human plasma and serum were obtained
from a local blood bank, and plasma clot matrices were
prepared from freshly obtained blood from 10 to 20 healthy
donors. FGF-2 was purchased from Pepro Tech EC (Lon-
don, UK) and human recombinant TNF-a from Sigma–
Aldrich Chemie (Steinheim, Germany). Factor XIII was
generously provided by Dr. H. Metzner and Dr. G. Seeman
(Aventis Behring GmbH, Marburg, Germany). Thrombin
was purchased from Leo Pharmaceutic Products (Weesp,
The Netherlands). The active avb3-blocking mAb LM609
and the avb5-blocking mAb P1F6 were purchased from
Chemicon (Temecula, CA). The a5-integrin blocking mAb
IIA1 was obtained from Pharmingen (Hamburg, Germany).
The a1-integrin blocking mAb 5E8D9 was obtained from
Upstate (Milton Keynes, UK). Endostatin was produced as
described by Yamaguchi et al. [36]. The biotinylated horse
anti-mouse IgG was obtained from Vector Laboratories
(Burlingame, CA) and the biotinylated donkey anti-rabbit
was purchased from Amersham Pharmacia Biotech UK
(Buckinghamshire, England). Rabbit anti-a5 and -b5 inte-
grins, both against the cytoplasmatic domain of the inte-
grin, were kindly provided by Dr. Guido Tarone
(University of Turin, Italy). The blocking anti-b1 mAb
P4C10 was obtained from Millipore (Billerica, MA). The
inhibitory anti-uPAR mAb H-2 was kindly donated by
Dr. U. Weidle (Boehringer Mannheim, Penzberg, Germany).
The human CD31 antigen, a monoclonal antibody, was
from Novocastra Laboratories, Newcastle, UK. Pepsin was
purchased from Sigma–Aldrich Chemie (Steinheim, Ger-
many). Biotinylated thyramides were obtained from the
Department of Endocrinology from the Leiden University
Medical Center (The Netherlands). The horseradish per-
oxidase (HRP) Avidin Biotinylated Complex was pur-
chased from DAKO (Glostrup, Denmark) and Novared
from Vector Laboratories (Burlingame, CA). Time speci-
mens of recanalized mural thrombi were kindly provided
by Dr. HW. Niessen (VU University Medical Center
Amsterdam, Department of Pathology, Amsterdam, The
Netherlands). cRGD, an av-inhibiting peptide and
GRGDSP, an RGD-inhibiting peptide were obtained from
Bachem (St. Helens, UK).
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Human foreskin microvascular cells (hMVECs) were iso-
lated, cultured and characterized as previously described
[39, 40].
Immunohistochemical analysis
Tissue sections of a recanalized human mural thrombus
were dewaxed by immersion in xylene and rehydrated in
decreasing concentrations of ethanol. For HPS staining, the
sections were counterstained with Mayer’s hematoxylin,
phloxin and saffron. After dehydration in a reversed
ethanol–xylene series, the sections were prepared for
microscopy.
Inhibition for endogenous peroxidase was accomplished
by immersion in 1% hydrogen peroxidase in absolute
methanol for 20 min at room temperature. The sections
were washed in deionized water and equilibrated in PBS.
Antigen retrieval for sections treated with anti-CD31 was
successful when the sections were incubated in 0.1 mol/l
sodium-citrate in a microwave at 700 W until boiling point
was reached, followed by a period of 10 min at 180 W. In
the case of LM609 and the rabbit anti-human antibody
against the a5-integrin, appropriate antigen retrieval was
reached when the sections were treated with 2 mg/ml
pepsin for 75 min at room temperature. For sections treated
with the rabbit anti-human antibody against the b5-inte-
grin, appropriate antigen retrieval was reached after a 10-
min incubation at room temperature with proteinase K.
Subsequently, all the sections were blocked by 5% BSA in
PBS to prevent nonspeciﬁc binding. Incubation with the
anti-CD31 (1:100), LM609 (10 lg/ml), anti-a5 (whole
rabbit serum diluted 1:400), and anti-b5 (whole rabbit
serum diluted 1:50) was done overnight at 4C. After
washes with PBS, the sections were exposed to the second
antibody, the biotinylated horse anti-mouse IgG (1:400) or
the donkey anti-rabbit (1:200) diluted in 1% BSA/PBS, for
1 h at room temperature. Afterwards, the sections were
washed with PBS and incubated for 30 min at room tem-
perature with the HRP Avidin Biotinylated Complex
(ABComplex). In order to amplify the signal of the sections
stained with the anti-b5-integrin, biotinylated thyramides
were added for 10 min at room temperature, followed
again by the HRP ABComplex for 30 min at room tem-
perature. The sections were washed with PBS and stained
with Novared for a period of 5–10 min. Finally, the sec-
tions were washed in aquadest, counterstained with
hematoxylin, washed in running water and dehydrated
in a reversed ethanol–xylene series, and prepared for
microscopy.
Preparation of the three-dimensional plasma and ﬁbrin
clots
Coagulation of plasma clots was performed as described by
Engelse et al. [41]. Brieﬂy, 2.5 U/ml Factor XIII and 1 U/
ml thrombin were added to human plasma, and 300 ll
aliquots of this mixture was added to the wells of a 48-well
plate. After clotting at room temperature for at least
30 min, the matrices were equilibrated at 37C, 5% CO2/
95% air atmosphere with serum-containing M199 to inac-
tivate the thrombin. During the next 24 h, the matrices
were washed three times with M199 to eliminate residual
citrate. Fibrin matrices were prepared as previously
described [11].
In vitro tube formation assay
The formation of capillary-like tubes in plasma-derived
ﬁbrinous matrices was evaluated essentially as previously
described in ﬁbrin matrices [11]. Conﬂuent hMVECs were
seeded on top of the matrices. After seeding 24 h, the cells
were stimulated with serum-containing M199 with or
without (control) the presence of FGF-2 and TNF-a and the
reagents to be tested. Every second day, the medium was
removed and replaced by fresh stimulation medium and
after 7 days, the formation of tubular structures was ana-
lyzed by phase contrast microscopy as previously described
[11].
ELISAs
u-PA antigen determinations as well as ﬁbrin degradation
products (FDP) determinations were performed by the
commercially available immunoassay kits: u-PA EIA HS
(Taurus, Leiden, The Netherlands) and Fibrinostika
 FDP
ELISA (Organon-Technika, Turnhout, Belgium). The
monoclonal antibodies that are used in this uPA ELISA
were made in our department and recognize all forms of
uPA: latent (single-chain) uPA, active (two-chain) uPA,
and u-PA complexed with PAI-1 in a similar manner
[11, 42].
Statistical analysis
Experiments were performed in duplicate and the results
were expressed as mean ± SEM in relation to the FGF-2/
TNF-a condition. For statistical analysis, we used one-way
ANOVA followed by the Dunnett’s test as post-test. The
Dunnett’s test is a modiﬁed t-test that takes into account
multiple comparisons with a control condition. Statistical
signiﬁcance was accepted at P\0.05.
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Endothelial cells in a ﬁbrinous matrix express
avb3-, avb5- and a5b1-integrins
Endothelial cells produce several integrins, three of which
have been reported to interact with ﬁbrin: avb5-, avb3-,
and a5b1-integrins. To verify the presence of these inte-
grins in new vascular structures formed in a ﬁbrinous
environment, immunohistochemical analysis of these
integrins was performed in tissue sections of a recanalized
human mural thrombus. As is shown in Fig. 1, avb3-inte-
grin, b5-containing integrins reﬂecting avb5-integrin, and
a5-containing integrins, representing a5b1 integrin, were
present in many vascular structures of these thrombi.
Involvement of RGD-binding integrins in the formation
of tubular structures in a 3D plasma-derived ﬁbrinous
matrix
To investigate the involvement of integrins in tube for-
mation in a human ﬁbrinous exudate, we used an in vitro
matrix consisting of clotted plasma to study the formation
of capillary-like tubes by human microvascular endothelial
cells (hMVECs). For that, hMVECs were cultured on top
of the plasma-derived ﬁbrinous matrix, and capillary-like
structures were formed after 4–6 days of culture in the
continuous presence of both FGF-2 (10 ng/ml) and TNF-a
(10 ng/ml), whereas addition of either FGF-2 or the
cytokine TNF-a hardly induced the formation of tubular
structures comparable to previous observations on
hMVEC-mediated tube formation in plasma-derived
ﬁbrinous matrices [41] and ﬁbrin matrices made using
puriﬁed ﬁbrinogen [11].
When echistatin (1 lg/ml), a general RGD inhibitor,
was added simultaneously with FGF-2/TNF-a to hMVECs
grown on a human plasma-derived ﬁbrinous matrix, hardly
any capillary-like structures were formed (18.6 ± 4.7% of
the amount formed by FGF-2/TNF-a-stimulated cells,
n = 3, P\0.001). The nature of the RGD-binding inte-
grins was further investigated using blocking mAbs against
a5b1-, avb3-, and avb5-integrins. Addition of either the
avb3-integrin blocking mAb LM609, the avb5-integrin
antagonist mAb P1F6, or the a5-integrin inhibiting mAb
IIA1 did not or only marginally affect the formation of
tubular structures in a plasma clot (Fig. 2a). Their effec-
tiveness was veriﬁed by their ability to inhibit cell binding
to ﬁbronectin by 61 ± 6% (mAb IIA1) or vitronectin-
coated dishes by 55 ± 7% (mAb LM609) and 40 ± 14%
(mAb P1F6). Interestingly, when mAb IIA1 was added
together with either LM609 or P1F6, the formation of
capillary-like structures was signiﬁcantly decreased. The
combination of anti-avb3 (LM609) and anti-a5 (IIA1)
integrins was most effective. Addition of anti-avb5 P1F6 to
the combination of mAb LM609 and mAb IIA1 resulted in
a further reduction of the formation of capillary-like
structures (Fig. 2a). Another mAb, 5E8D9, that blocks the
a1-integrin, did not affect tube formation neither by itself
Fig. 1 Localization of RGD-binding integrins in endothelial cells
in vivo. Immunohistochemistry was performed on parafﬁn sections
of a recanalized mural thrombus formed in a human coronary
artery as described in Materials and Methods. a Phloxin staining;
b Immunostaining of endothelial cells by CD31; c Immunostaining of
avb3-integrin by mAb LM609; d Immunostaining of avb5-integrin
by rabbit anti-human b5-integrin antibody; e Immunostaining of
a5b1-integrin by rabbit anti-human a5-integrin antibody
278 Angiogenesis (2009) 12:275–285
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(86 ± 2 and 82 ± 1 of control, respectively). The b1-
integrin blocking mAb P4C10, which inhibits a5b1- and
a3b1-integrins, had no effect on tube formation when
added as a single antibody (data not shown).
The presence of either mAb LM609 or mAb IIA1
during the tube formation assay did not affect cell
attachment, once the cells had been seeded on top of a
plasma-derived ﬁbrinous matrix (compare the intact
monolayer of cells in Fig. 2b). No apoptotic cells were
observed in the presence of integrin inhibitors as deter-
mined by the absence of fragmentation of nuclei, after
DAPI staining and evaluation by digital imaging micros-
copy (data not shown).
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Fig. 2 Blocking of avb3- and
a5b1-integrins results in a
combined effect on the
inhibition of capillary-like tube
formation in plasma-derived
ﬁbrinous matrices. HMVECs
cultured on a three-dimensional
ﬁbrinous plasma clot were not
stimulated (control) or
stimulated with FGF-2/TNF-a
in the absence or presence of the
avb3-blocking mAb LM609
(10 lg/ml), the avb5-blocking
mAb P1F6 (10 lg/ml), the a5-
blocking mAb IIA1 (2 lg/ml)
or the combinations of these
mAbs. After 6 days of
culturing, the mean tube length
of duplicate wells was
quantiﬁed (mm/cm
2)a s
described (a). The data
represent mean % ± SEM of
FGF-2/TNF-a stimulated tube
formation of 3–7 independent
experiments. The mean tube
length of FGF-2/TNF-a in the
plasma-derived ﬁbrinous matrix
was 70 ± 20 mm/cm
2. b After
6 days of culturing, non-phase
photomicrographs were taken of
hMVECs stimulated with FGF-
2/TNF-a in the absence or
presence of LM609, IIA1 or the
combination of these mAbs in
the concentrations described
above. Bar represents 300 lm.
* P\0.01 as compared to
100% (=FGF-2/TNF-a
stimulated condition)
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affects u-PA and FDP production
The reduced ingrowth of capillary-like structures after
exposure to mAb LM609 and mAb IIA1 was accompanied
by a reduced accumulation of u-PA in the conditioned
medium of the tube-forming cells (Table 1). Furthermore,
the reduced formation of tubular structures was paralleled
by a decreased generation of ﬁbrin degradation products
(Table 1). The individual antibodies hardly affected these
parameters. This suggests that the simultaneous interfer-
ence with avb3- and a5b1-integrins results in a diminished
u-PA accumulation in the supernatants of the FGF-2/TNF-
a-treated cells and a diminished generation of FDP prod-
ucts. Experiments using the uPA receptor (uPAR) blocking
antibody H-2 indicated that the differences in uPA were not
due to decreased uPAR availability on the endothelial cells.
The mAb H-2 displaces uPA from the uPAR and thereby
prevents the uptake and degradation of uPA by the endo-
thelial cells. In the presence of mAb H-2, the accumulation
of uPA in the conditioned medium increased by 160–180%
in all conditions as compared with each counterpart with-
out H-2.
Endostatin acts in concert with mAb LM609 and cRGD
in inhibiting capillary-like tube formation
Endostatin, at a concentration of 10 lg/ml, affected the
FGF-2/TNF-a-induced formation of tubular structures by
hMVECs in a plasma-derived ﬁbrinous matrix minimally
(Fig. 3). When endostatin was given simultaneously with
mAb LM609, but not with mAb IIA1, the formation of
tubular structures was largely inhibited (Fig. 3). Appar-
ently, endostatin was able to mimic the effect of a a5-
integrin blocking e.g., mAb IIA1 (compare Fig. 3 and 2a).
The interaction of a5b1- and avb3-integrins was further
underscored using cyclic RGD peptides with speciﬁcity for
av-integrins [43]. While the formation of capillary-like
structures in the plasma clot was minimally affected by the
addition of cRGD or endostatin alone, tube formation was
largely inhibited when cRGD and endostatin were added
simultaneously (Fig. 3). A similar inhibition was achieved
by simultaneous addition of cRGD and mAb IIA1 (Fig. 3).
These results indicate that cRGD and endostatin inhibited
the formation of tubes to the same extent as mAb LM609
and endostatin.
Tube formation in a ﬁbrinous exudate requires
interaction between ﬁbrin and RGD-binding integrins
The plasma clot consists of various matrix proteins that
contain RGD-sequences, in particular ﬁbrin, ﬁbronectin and
vitronectin. While the RGD-sequences in vitronectin of
human and mice are comparably organized, the RGD-
sequences in the Aa-chain of ﬁbrinogen are markedly dif-
ferent. Therefore, we investigated whether the effects of
integrininhibitorswerecomparable,whenhMVECsformed
tubular structures in a ﬁbrin matrix prepared from puriﬁed
ﬁbrinogen. As is shown in Fig. 4, addition of integrin
inhibitors, in particular against a5b1- and avb3-integrins,
largely reduced tube formation in a ﬁbrin matrix. These data
suggest that ﬁbrin largely determines integrin requirement
for tube formation in a plasma-derived ﬁbrinous matrix.
Discussion
In this report we demonstrate the interplay of avb3-, avb5-
and a5b1-integrins in the formation of capillary-like
structures in a 3-D in vitro plasma-derived ﬁbrinous matrix.
In the 3D-ﬁbrinous matrix, tube formation was only largely
inhibited when integrin antagonists were used together, in
particular those blocking the avb3- together with the a5b1-
integrins. Accordingly, endostatin in combination with
Table 1 Simultaneous blocking of avb3- and a5b1-integrins induces inhibition of tube formation as well as a decrease of u-PA production and
FDP formation
Tube formation (% of control) uPA accumulation (% of control) FDP formation (% of control)
FGF-2/TNF-a 100 100 100
FGF-2/TNF-a ? LM609 88.9 ± 9.4 69.1 ± 10.7 93.0 ± 9.2
FGF-2/TNF-a ? IIA1 95.1 ± 9.5 84.2 ± 6.7 106.7 ± 22.7
FGF-2/TNF-a ? LM609 ? IIA1 22.7 ± 1.6* 56.3 ± 12.3* 58.8 ± 8.0**
HMVECs were cultured on a three-dimensional plasma matrix with FGF-2 (10 ng/ml) and TNF-a (10 ng/ml) to induce capillary-like tubular
structures, in the absence or presence of the avb3-blocking mAb LM609 (10 lg/ml), the a5-blocking mAb IIA1 (2 lg/ml) or the combination of
these mAbs. After 6 days of culturing, the mean tube length of duplicate wells was quantiﬁed (mm/cm
2) as described. The accumulation of u-PA
antigen (100 = 22.6 ng/10
5 cells/6 days as determined by summation of three 48 h conditioned media) and the formation of ﬁbrin degradation
products (100 = 1,110 ng/10
5 cells in total after 6 days) were determined in the conditioned media by ELISA and expressed as percentage of the
FGF-2/TNF-a control. The data represent mean ± SEM of 4 independent experiments
* P\0.01; ** P\0.05 as compared to 100% (=FGF-2/TNF-a-stimulated condition)
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competing cyclic-RGD peptide induced a dramatic
decrease of tube formation, while endostatin alone had only
a minimal effect. These data suggest that integrin-mediated
interactions of endothelial cells with a ﬁbrinous matrix are
required for, but also support survival of, capillary tube
formation by these cells.
The ﬁbrinous exudates formed in wounds and tumor
stroma are considered as supporting matrices for angio-
genesis [4, 44, 45]. Our data indicate that the formation of
capillary-like tubular structures in vitro proceeds similarly
in a ﬁbrin matrix prepared from puriﬁed ﬁbrinogen and in a
ﬁbrinous exudate matrix prepared from plasma. Therefore,
the focus was on the ﬁbrin-recognizing integrins avb3,
avb5 and a5b1, which have been implicated inangiogenesis
[15, 16, 21, 46, 47]. These ﬁbrin-binding integrins were
present on the endothelium of newly formed vessels in a
recanalized mural thrombus and conform previous reports
[48–50]. The RGD-integrin inhibiting agent echistatin
completely inhibited the FGF-2/TNF-a-induced formation
of capillary-like structures by hMVECs, indicating that
RGD-containing integrins were essential for neovasculari-
zation [15, 16, 21, 46]. Furthermore, our data indicate that a
complete inhibition of capillary-like tube formation
requires the simultaneous inhibition of these integrins, in
particular the avb3- and a5b1-integrins. These data com-
pare well with those of integrin inhibiting antibodies on the
reorganization of endothelial cells embedded in a three-
dimensional ﬁbrin matrix [51]. The mutual interaction of
a5b1-integrin and av-containing integrins, in particular
avb3-integrin was underscored by using two unrelated
types of inhibitors for the a5b1-integrin (mAb IIA1, endo-
statin) and the avb3-integrin (mAb LM609, cRGD), which
make inhibitor-speciﬁc effects less likely. Several recent
reports have pointed to the induction of apoptosis in
endothelial cells as a cause of angiogenesis inhibition by
ligands of the avb3-integrin, such as mAb LM609 and
tumstatin [34]. Our in vitro data did not provide direct
evidence of the occurrence of such mechanism in endo-
thelial cells that were in contact with a ﬁbrinous matrix.
This suggests that the interaction of hMVECs with the ﬁbrin
matrix may provide signals into the cells that protect them
from going into apoptosis, once avb3-integrin is blocked. In
this context, it should be noted that the adhesive potential of
endothelial cells to bind ﬁbrin(ogen) depends on transglu-
taminase and FXIIIa [52]. Oligomerization of the aC-
domains of ﬁbrinogen by transglutaminase, stimulates their
ability to bind avb3-, avb5-, and a5b1-integrins on
150 150
75
100
125
%
 
o
f
 
F
G
F
-
2
/
T
N
F
 
 
 
 
)
-
*
*
75
100
125
%
 
o
f
 
F
G
F
-
2
/
T
N
F
 
 
 
 
)
-
α
*
*
25
50
m
e
a
n
 
t
u
b
e
 
l
e
n
g
t
h
 
(
%
**
** **
**
25
50
m
e
a
n
 
t
u
b
e
 
l
e
n
g
t
h
 
(
%
**
** **
**
0
Control
FGF-2 + TNF
Endostatin
LM609
IIA1
cRGD
LM609 + Endostatin
IIA1 + Endostatin
cRGD + Endostatin
IIA1 + cRGD
FGF-2 + TNF
0
Control
FGF-2 + TNF
Endostatin
LM609
IIA1
cRGD
LM609 + Endostatin
IIA1 + Endostatin
cRGD + Endostatin
IIA1 + cRGD
FGF-2 + TNFα
Fig. 3 Combined effect of endostatin, LM609, and/or cRGD on
capillary-like tube formation in ﬁbrinous plasma clots. HMVECs
cultured on a three-dimensional plasma clot were not stimulated
(control) or stimulated with FGF-2/TNF-a in the presence of either
endostatin (10 lg/ml), the avb3-blocking mAb LM609 (10 lg/ml),
the a5-blocking mAb IIA1 (2 lg/ml) or cRGD (50 lg/ml), a
combination of endostatin and LM609, endostatin and IIA1, cRGD
and endostatin, or IIA1 and cRGD. After 6 days of culturing, the
mean tube length was quantiﬁed (mm/cm
2) as described. The data
represent mean % ± SEM of FGF-2/TNF-a stimulated tube forma-
tion of 3–5 independent experiments. The mean tube length of FGF-2/
TNF-a was 98 ± 15 mm/cm
2.*P\0.05, ** P\0.01 as compared
to 100% (=FGF-2/TNF-a stimulated condition)
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123endothelial cells. The oligomerization did not only increase
cell adhesion, but also promoted integrin-dependent cell
signaling via focal adhesion kinase (FAK) and extracellular
signal regulated kinase (ERK) [53].
Our data suggest that integrin–ﬁbrin interactions were
dominant in the plasma-derived ﬁbrinous matrix, because a
similar effect was observed with puriﬁed ﬁbrin matrices as
with plasma-derived ﬁbrinous matrices. This directs the
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Fig. 4 Blocking of avb3- and a5b1-integrins results in a combined
effect on the inhibition of capillary-like tube formation in puriﬁed
ﬁbrin matrices. HMVECs cultured on a three-dimensional ﬁbrin
matrix and were not stimulated (control) or stimulated with FGF-2/
TNF-a in the absence or presence of the avb3-blocking mAb LM609
(10 lg/ml), the avb5-blocking mAb P1F6 (10 lg/ml), the a5-
blocking mAb IIA1 (2 lg/ml) or the combinations of these mAbs.
After 6 days of culturing, the mean tube length of duplicate wells was
quantiﬁed (mm/cm
2) as described (a). The data represent mean
% ± SEM of FGF-2/TNF-a stimulated tube formation of 3–7
independent experiments. The mean tube length of FGF-2/TNF-a in
the puriﬁed ﬁbrin matrix was 83 ± 4 mm/cm
2. b After 6 days of
culturing, non-phase photomicrographs were taken of hMVECs
stimulated with FGF-2/TNF-a in the absence or presence of
LM609, IIA1 or the combination of these mAbs in the concentrations
described above. Bar represents 300 lm. *P\0.01 as compared to
100% (=FGF-2/TNF-a stimulated condition)
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123attention to the RGD-sequences in ﬁbrin, of which the
RGD-sequence 572–574 in the Aa-chain of human ﬁbrin-
ogen plays a major role in the invasion of hMVECs in a
ﬁbrin matrix [54–56]. Interestingly, this RGD-sequence is
absent in mouse ﬁbrinogen (Fig. 5), while three additional
RGD-sequences were present between position 272 and
286 in the murine Aa-chain (compare human and mouse
Aa-chain in Fig. 5). Thiagarajan et al. [54] have demon-
strated that in the bovine ﬁbrinogen the RGD-sequence at
position 272–274, which is homologous to an RGG in
human ﬁbrinogen, can mediate endothelial cell adhesion. It
is likely that this substitution plays a similar role in the
murine ﬁbrinogen. However, given the importance of the
ﬂanking regions in the speciﬁcity of the RGD-sequences
data from mouse and man must be compared with cau-
tiousness. Furthermore, we can not exclude an indirect
additional role for integrin a3b1, which was reported to
affect endothelial cell adhesion [57] and migration [58].
However, such effect will be limited, as inhibition of b1-
integrins alone did not signiﬁcantly alter endothelial tube
formation in a ﬁbrinous matrix.
In the ﬁbrinous matrix, the inhibitory effect of endo-
statin is highly compatible with a5b1-integrin blocking
activity. Although endostatin does not contain an RGD-
sequence, it can interact with RGD-binding integrins,
particularly a5b1-integrin [33], similar to the binding of the
C-terminus of MMP-2 to RGD-dependent integrins [59].
Our in vitro data demonstrate that blocking of only one
integrin is not sufﬁcient for complete inhibition of tube
formation by human MVEC in a human ﬁbrin or plasma
clot, but requires the simultaneous inhibition of avb3- and
a5b1-integrins. Our data, as well as the recent ﬁndings of
Carnevale et al. [60], support the use of a combined
administration of avb3- and a5b1-integrin antagonists to
block angiogenesis in an experimental setting. They
showed that blocking of both b1- and b3-integrins resulted
in inhibition of tube formation in ﬁbrin matrices using the
rat aortic ring model, whereas blocking of only one of the
integrins was ineffective. Using collagen matrices they
found that b1-integrins, but not b3-integrins were required
for angiogenic sprouting. These data indicate that the
integrin requirements may vary for neovessel formation,
dependent on the composition of the ECM. Indeed, endo-
thelial cells overexpress avb3-integrin when exposed to
ﬁbrin and during wound healing in a ﬁbrin rich matrix,
vascular cells transiently express avb3-integrin [26, 61].
Moreover, Bayless et al. [62] reported that the integrin-
dependent spingosine-1-phosphate regulates endothelial
cell invasion, lumen formation, and branching morpho-
genesis in ﬁbrin matrices, which is dependent on both
avb3- and a5b1-integrins.
Although the involvement of particular integrin combi-
nations, essential for angiogenesis, remains controversial, it
is likely that multiple integrin attack prevents compensa-
tory mechanisms. And our ﬁnding demonstrates the ﬂexi-
bility of the angiogenesis process in a temporary ﬁbrin
matrix. Moreover, it also may bear impact on the use of
inhibitors of speciﬁc integrins for anti-angiogenesis treat-
ment [63, 64]. After initial damage of the blood vessel by
blocking agents of individual integrins, the formation of
a ﬁbrinous exudate may support survival of endothelial
cells.
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Fig. 5 Analysis of the human
and mouse ﬁbrinogen. Scanning
electron microscopy of human
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